Skip to main content

Table 2 Univariable and multivariable analysis of factors associated with overall survival

From: Early tumor shrinkage and response assessment according to mRECIST predict overall survival in hepatocellular carcinoma patients under sorafenib

Parameter Univariate analysis Multivariate analysis
HR (95% CI) p value HR (95% CI) p value
Best response (CR + PR vs. SD + PD) 0.38 (0.22–0.63) < 0.0001 0.32 (0.18–0.55) < 0.001
Sex (male vs. female) 0.50 (0.27–0.91) 0.0241 0.41 (0.22–0.75) 0.004
Age (≥65 vs. < 65 years) 1.01 (0.67–1.54) 0.9310  
ECOG (1 vs. 0) 0.80 (0.48–1.35) 0.4184
Cirrhosis (yes vs. no) 1.22 (0.63–2.37) 0.5457
Hepatitis B etiology (yes vs. no) 1.22 (0.61–2.44) 0.5677
Hepatitis C etiology (yes vs. no) 1.17 (0.74–1.85) 0.4847
Alcohol etiology (yes vs. no) 0.78 (0.51–1.21) 0.2798
TACE history (yes vs. no) 0.86 (0.54–1.37) 0.5434
PVI (yes vs. no) 1.10 (0.73–1.67) 0.6260
Child-Pugh (B vs. A) 1.59 (0.78–3.20) 0.1950
BCLC (C vs. B) 1.06 (0.67–1.67) 0.7845
Beyond up-to-7 (yes vs. no) 1.28 (0.66–2.47) 0.4636
Bilirubin (≥17 vs. < 17 μmol/L) 1.55 (1.02–2.36) 0.0391
Albumin (≥36 vs. < 36 g/L) 0.66 (0.42–1.04) 0.0759
ALBI (grade 2/3 vs. grade 1) 1.74 (1.14–2.66) 0.0091 1.88 (1.21–2.92) 0.005
AFP (≥400 vs. < 400 ng/mL) 1.06 (0.67–1.66) 0.8012  
  1. All covariates were time-fixed except for best response, which was time dependent
  2. AFP alfa-fetoprotein, ALBI albumin-bilirubin, BCLC Barcelona Clinic Liver Cancer, CR complete response, ECOG Eastern Cooperative Oncology Group, HR hazard ratio, PD progressive disease, PR partial response, PVI portal vein invasion, SD stable disease, TACE transarterial chemoembolization